Budenofalk治疗哮喘效果如何？

Has significant lipophilicity and is rapidly absorbed in the intestine due to good tissue permeability. Compared to classical GCS, budesonide has a very high affinity for the receptor. Due to these attributes, Budenofalk has a purposeful place to act. About 90% of budesonide is metabolized in the liver on first pass, and only about 10% has systemic effects. Of this amount, 90% of Budenofalk is bound to albumin, and for this reason it has a biologically inert form. Budenofalk is approved for use in patients with glucocorticoid-dependent or -independent bronchial asthma and asthmatic chronic bronchitis.

How effective is Budenofalk in treating asthma?

The MIST trial enrolled children with modified API positivity, recurrent wheezing, and ≥1 exacerbation in the past year but with low severity (defined as infrequent albuterol use and infrequent nocturnal awakenings between exacerbations). All subjects first received pretreatment with nightly placebo doses of budesonide inhalation suspension for 2 weeks (run-in period) and albuterol if necessary, and then received 52 weeks (treatment period) of randomized treatment. The intermittent treatment group (n=139) received 1 mg Budenofalk inhalation suspension twice a day for 7 days after the respiratory disease was diagnosed; the daily treatment group (n=139) received 0.5 mg Budesonide inhalation suspension every night. Each group was also given a corresponding placebo dose of the drug.

The results showed that the incidence rates of asthma exacerbation in the treatment group and intermittent treatment group were 0.97/(patient·year) and 0.95/(patient·year) respectively, and the relative incidence rate in the intermittent treatment group was 0.99. The incidence rates of non-serious adverse events and serious adverse events were also similar between the two groups, but the average cumulative exposure of budesonide in the intermittent treatment group was significantly smaller than that in the daily treatment group (45.7 mg vs 149.9 mg).